New Life Biologics
Private Company
Funding information not available
Overview
New Life Biologics is a private, commercial-stage biotechnology company specializing in the development and manufacturing of animal-derived biological products, primarily for the cell culture and diagnostics markets. Its core innovation is a proprietary plasma fractionation platform that creates sustainable, powder-form alternatives to traditional FBS and enhanced BSA products, addressing key industry pain points like batch variability, contamination risk, and supply chain instability. The company appears to be revenue-generating, selling directly to end-users in research and diagnostics, and is actively promoting its technology at industry conferences. Its strategic focus is on displacing incumbent serum products with more reliable and sustainable solutions.
Technology Platform
Proprietary plasma fractionation technology for separating and purifying components from bovine plasma, featuring viral kill steps and powder formulation for stable, cold-chain-free products.
Opportunities
Risk Factors
Competitive Landscape
New Life Biologics competes with large, diversified life science tools companies like Thermo Fisher Scientific, Merck (Sigma-Aldrich), and Cytiva that dominate the serum and protein reagent market. It also faces competition from other FBS-alternative developers and companies promoting recombinant or plant-derived proteins for cell culture.